Clinical Trial Update: A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating the combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in relapsed/refractory multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING